

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number
WO 2005/049578 A1

(51) International Patent Classification⁷: C07D 231/14, 409/10, 405/10, 401/10, 231/12, A61K 31/415, A61P 3/00

(74) Agent: LEARROYD, Stephanie, Anne; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(21) International Application Number:

PCT/EP2004/012965

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data:

0326747.3 17 November 2003 (17.11.2003) GB
0329462.6 19 December 2003 (19.12.2003) GB

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CII, CY, CZ, DE, DK, EB, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US):


SMITHKLINE BEECHAM CORPORATION
{US/US}; One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PYRAZOLES AS PPAR AGONISTS



(57) Abstract: A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof (I) wherein: p is 0 or 1; q is 0 or 1; R¹ and R² are independently H or C₁₋₃ alkyl; R³ and R⁴ are independently H, C₁₋₆ alkyl, -OC₁₋₆ alkyl, halogen, OH, C₂₋₆ alkenyl or CF₃; R⁵ is H, C₁₋₆ alkyl (optionally substituted by one or more halogens, -COphenyl, OC₁₋₆ alkyl, phenyl morpholino or C₂₋₆ alkenyl). R⁶ is C₁₋₆ alkyl, halogen, -OCH₂ phenyl, phenyl (optionally substituted by C₁₋₃ alkyl), morpholino, pyrrolidino, piperidino, thiophenyl, furanyl pyridinyl or -OC₂₋₆ alkenyl. These compounds activate the alpha and gamma subtypes of the hppar receptor and are useful e.g. in the treatment of diabetes, dyslipidemia or syndrome X.

WO 2005/049578 A1